FDA approves first 'digital pill' to track patients

FDA approves first 'digital pill' to track patients

FDA approves first 'digital pill' to track patients

Abilify MyCite is the first pill of its kind to get FDA approval, though, paving the way for a new kind of drug that may aid in patient compliance.

The treatment is called Abilify MyCite, which is meant to treat schizophrenia, acute treatment of manic and mixed episodes associated with bipolar disorder, and for use as an add-on treatment for depression in adults.

A patient ingests the pill, and a sensor inside the pill activates when it reaches the stomach fluids, sending a message to a wearable patch.

And Otsuka is aware that Abilify MyCite is a more complicated product than the usual pill, and it'll be more hard to market, too.

Not necessarily. Abilify MyCite notes under its label that the product's ability to improve patient compliance with their treatment regimen has not been shown.

Aripiprazole is used to treat multiple mental mood disorders, including bipolar disorder and schizophrenia.

Using an app on their smartphone, patients can keep track of their dosage and allow their physicians to access information through a website.

Sergio Aguero Reportedly Fainted in Argentina Locker Room, Underwent Examination
Super Eagles coach Gernot Rohr is delighted with his team's comeback win against Argentina. He ought to take the blame for the second goal against Nigeria due to his bad positioning.

The new product, which will be sold as Abilify MyCite, can be swallowed just like any other pill.

Elderly patients with dementia-related psychosis treated with antipsyhotic drugs, such as Abilify MyCite, are at an increased risk of death. A report from the IMS Institute for Healthcare Informatics estimates that the cost of patients not taking their medication correctly is about $100 billion each year.

Forgetfulness and cloudy thinking can be symptoms of the mental health conditions that Abilify is approved to treat, and patients with mental illness are known to struggle to take medication consistently.

Abilify MyCite's future isn't certain, however.

The FDA-approved pill, Abilify MyCite, consists of aripiprazole tablets, but with a sensor.

Patients taking Abilify MyCite should be monitored for worsening or emerging suicidal thoughts and behaviors. Skin irritation at the site of the MyCite patch placement may occur in some patients.

The technology is the product of research between Japanese pharmaceutical company Otsuka and Proteus Digital Health, and is created to solve the problem of people missing medicine doses, which costs the US healthcare system an estimated $200 billion per year. This first USA approval could bode well for other new products in the works, including sensor-embedded versions of generic blood pressure pill lisinopril and the standard diabetes drug metformin.

Related news